Tricida Inc (NASDAQ:TCDA) insider Gerrit Klaerner sold 57,822 shares of the firm’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $32.96, for a total value of $1,905,813.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Gerrit Klaerner also recently made the following trade(s):
- On Monday, March 4th, Gerrit Klaerner sold 8,000 shares of Tricida stock. The shares were sold at an average price of $23.92, for a total value of $191,360.00.
NASDAQ TCDA opened at $31.16 on Friday. Tricida Inc has a twelve month low of $19.43 and a twelve month high of $40.83. The company has a quick ratio of 16.51, a current ratio of 16.50 and a debt-to-equity ratio of 0.20.
A number of equities research analysts have weighed in on the company. Zacks Investment Research downgraded Tricida from a “buy” rating to a “hold” rating in a research report on Thursday, April 11th. Empire raised their price target on Tricida from $37.00 to $58.00 in a research report on Monday, April 1st.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Strs Ohio increased its holdings in shares of Tricida by 45.5% in the first quarter. Strs Ohio now owns 4,800 shares of the company’s stock worth $185,000 after buying an additional 1,500 shares during the period. Geode Capital Management LLC grew its stake in shares of Tricida by 8.5% in the fourth quarter. Geode Capital Management LLC now owns 188,925 shares of the company’s stock worth $4,454,000 after purchasing an additional 14,741 shares during the last quarter. Norges Bank bought a new stake in shares of Tricida in the fourth quarter worth about $236,000. Amundi Pioneer Asset Management Inc. bought a new stake in shares of Tricida in the fourth quarter worth about $99,000. Finally, Opaleye Management Inc. grew its stake in shares of Tricida by 141.2% in the fourth quarter. Opaleye Management Inc. now owns 123,000 shares of the company’s stock worth $2,900,000 after purchasing an additional 72,000 shares during the last quarter. Hedge funds and other institutional investors own 69.36% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/tricida-inc-tcda-insider-gerrit-klaerner-sells-57822-shares.html.
Tricida Company Profile
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Further Reading: How interest rates affect municipal bond prices
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.